Jordi Martorell, Aortyx - Aortic Dissection Treatment | LSI Europe '22

Transcription

Jordi Martorell  0:06  

Aortic is one of the largest arteries in our body, and it's definitely the most important. Now it's like river life flows through it. However, as with any organ, it can suffer from damage and in this case, what we're seeing here, and then reason which is an over expansion of the euro. This is a highly prevalent and requires more than 300,000 procedures per year. And when these worsens, elicit a dissection, which is a tear in the aortic wall that causes obviously, severe damage can cause ischemia, and especially can cause up to 50% mortality. Despite the severity, current treatments present severe limitations and must be replaced in our in open repair. And it's still the preferred option by physicians, we basically crack open the chest and just replace the damaged vessel with a graft. This is extremely invasive and has a mortality of up to 30% in those patients. To overcome this invasiveness in the vascular repair was developed to reduce the mortality. So in the industry, where what we have is a graph that is delivered via a stent, and that is placed in the artery. This is much less invasive and carries less mortality. But only 20% of patients are actually eligible. And it carries a fake failure rates of up to 50% due to mechanical mismatch between the pulsing aorta and the stiff device for those patients and fit for, for any of these surgeries. We have medical therapy, but this has successfully it's just unacceptable. At every vascular surgery conference we attend, we are told by surgeons that we need their devices for the Aorta and but we also need to protect and preserve the vessel. And faced with his unmet clinical need Aortyx was founded to change the paradigm of how your diseases should be treated. And we the founders are a perfect combination of chemists engineers, but also one of the top 10 uric surgeons in the world, the Korean bow, the team has now increased to 16 Amazing members that are enthusiastic but also even have joined from like the established industry to do some outdoor adventure. We have invented and patented a disruptive device. It consists of a patch that is delivered using a catheter. This bendable catheter catheter oriented against the entertainer deploys and adheres against the aortic wall. And the patch has a patented microstructure that allows for two things. One, it has the same mechanical properties as the euro, so it pulses with the euro, but also its microstructure allows for a biological integration within the tissue. So we are preserving the euro, especially as our physicians were asking, and we have developed the entire device, including the catheters, the Deployer, and the patch and interfaces. These are only drawings No, but the reality is, it's really coming No. And what he has seen is that in animals, the patch adheres perfectly against the uric wall and resist 10,000 times the strength of blood flow. And also as you can see in the video, the patch moves and pulses along with the aortic. So we have no more mechanical mismatch between the device and the vessel. We have seen know how after implantation cells start climbing on top of the patch are able to regenerate the entire surface. But not only that, when we create a dissection, the patch is able to stop the bleeding and to initiate also a fibrosis and a hardening of the of the of the area so we are actually healing the wound. We have also designed the catheter in here in this video is a little more compacted, they should be able to navigate any complex geometries. As we can see in this video, we are able to deploy it in in a cadaver. So we have been able to design a catheter that fits all of our needs all our required requirements. This is a brief summary of the work was done over the last three years. And this work has been funded by two successful business angel rounds with about 3 million years and we have raised more than 4.5 million in private sorry in public competitive grants. But this is the test no the future is exciting. We're now raising 12 million euros series A to finalize all the regulatory For technical, the manufacturing process, and to be able to go into first inhuman. And with all these milestones will reach a value inflection point so that we can go for a bit FDA breakthrough device designation, and then go for a pivotal trial in the US and in Europe. The idea is to not only work in a section, but also as I'll show you later, we'll have a pipeline. So in this series, we will also fit the pipeline of products. The structure of the series A is gaining traction, and we have a we are aware it is of an AC accelerator. So the European Commission will invest three point 75 million, and we have a lead investor who wants who's Barcelona, VC based, is another capital. And then we are looking for the other 6 million in conferences like today, and we hope that we're able to finish the round in first quarter 2023. This investment is backed by a significant market opportunity only focused on the aortic dissection, it will exceed 550 million euros in 2025. But this is only the session, as I told you, we're developing a pipeline where we can use our patent as a platform for more indications, especially in the auric field, starting with the European organisms that have a much larger market. So a combined market of more than 3 billion euros. And we are designing this pipeline not to become the revolution that the iPhone was the old phones. Basically, we want to tackle know, the most significant unique diseases with a revolution, a revolutionary system, a revolutionary platform. So we're adding drug delivery capacity to treat the organisms, but you're also developing a system to attract gene therapy only to localized points in the euro. This whole thing is backed by a market that is very intense. Now the the manufacturers are looking for the next revolution in our in the auric field. These devices the first endovascular treatments were developed in the 90s. And we have not seen any significant evolution. These devices have been acquired. But imagine the value of an of a solution that is actually disruptive. We ask everyone in the audience always to have a healthy life and to reduce the risk of suffering from a uric disease. We also ask investors to trust us and support us in our journey in our change for them. And so we ask all to think of Aortyx and to think Eric's certainly